Steven Feldman to Models, Economic
This is a "connection" page, showing publications Steven Feldman has written about Models, Economic.
Connection Strength
1.051
-
Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
Score: 0.473
-
Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.
Score: 0.154
-
Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 May; 67(5):708-17.
Score: 0.127
-
Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
Score: 0.090
-
Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface. 2006 Jan; 19(1):33-6, 39.
Score: 0.067
-
Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatol Online J. 2005 Mar 01; 11(1):1.
Score: 0.063
-
Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003 Sep; 4(9):1525-33.
Score: 0.057
-
Inglese MJ, Fleischer AB, Feldman SR, Balkrishnan R. The pharmacoeconomics of acne treatment: where are we heading? J Dermatolog Treat. 2008; 19(1):27-37.
Score: 0.019